Tirzepatide: what the research shows.

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. Developed by Eli Lilly, it is approved in the United States as Mounjaro for type 2 diabetes and Zepbound for obesity, and is given as a once-weekly injection in clinical dosing.

That approved status matters: tirzepatide is a regulated prescription medicine, and any product marketed as "research-grade tirzepatide" is sold outside that regulatory system. Our coverage here is educational.

How it works: dual receptor agonism

• GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion — the same core pathway as semaglutide.
• GIP receptor activation is the addition. GIP also stimulates insulin and appears to act on fat tissue, and the combination produces larger metabolic effects than GLP-1 alone at comparable doses.

Retatrutide adds a third receptor to this same design idea; see our retatrutide guide for how it extends the approach.

What researchers are studying

• Obesity and weight management (SURMOUNT program)
• Glycemic control in type 2 diabetes (SURPASS program)
• Obstructive sleep apnea and cardiovascular risk markers
• Comparisons with single GLP-1 agonists, as in our semaglutide vs tirzepatide article

What the research shows

• SURMOUNT-1 (NEJM, 2022; ~2,500 adults with obesity): mean weight reduction of 20.9% at the 15 mg dose over 72 weeks, versus about 3% on placebo.
• SURPASS trials in type 2 diabetes showed HbA1c reductions that exceeded several active comparators.
• Gastrointestinal effects — nausea, vomiting, diarrhea — were the most common adverse events, concentrated during dose escalation.

Research limitations

• Trial populations are screened and supervised; real-world adherence and tolerability differ.
• Long-term (5+ year) safety data is still accumulating through post-approval surveillance.
• Approved use is under medical supervision with defined dosing — outside that context, safety and authenticity are unmonitored, which is why batch-specific COAs matter if you encounter research-grade material.

Common terminology

• Dual agonist — a molecule activating two receptors.
• Incretins — gut hormones (GLP-1, GIP) that stimulate insulin after meals.
• HbA1c — a laboratory measure of average blood glucose over months.
• Dose escalation — gradually increasing doses to improve tolerability.